Synthesis and Anti-inflammatory Evaluation of Novel Benzimidazole and Imidazopyridine Derivatives.

Sepsis, an acute inflammatory disease, remains the most common cause of death in intensive care units. A series of benzimidazole and imidazopyridine derivatives were synthesized and screened for anti-inflammatory activities, and the imidazopyridine series showed excellent inhibition of the expression of inflammatory cytokines in LPS-stimulated macrophages. Compounds X10, X12, X13, X14, and X15 inhibited TNF-α and IL-6 release in a dose-dependent manner, and X12 showed no cytotoxicity in hepatic cells. Furthermore, X12 exhibited a significant protection against LPS-induced septic death in mouse models. Together, these data present a series of new imidazopyridines with potential therapeutic effects in acute inflammatory diseases.

[1]  K. Nguyen,et al.  Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. , 2012, Journal of medicinal chemistry.

[2]  F. Ye,et al.  Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. , 2011, Journal of medicinal chemistry.

[3]  Benjamin Tang,et al.  Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis , 2011, Critical care.

[4]  Jian Xiao,et al.  A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. , 2011, Journal of medicinal chemistry.

[5]  Liang-Jen Wang,et al.  Zolpidem dependence and withdrawal seizure--report of two cases. , 2011, Psychiatria Danubina.

[6]  J. Marshall,et al.  The Global Sepsis Alliance: building new collaborations to confront an under-recognized threat. , 2011, Surgical infections.

[7]  K. Hahm,et al.  Novel Application of Proton Pump Inhibitor for the Prevention of Colitis-Induced Colorectal Carcinogenesis beyond Acid Suppression , 2010, Cancer Prevention Research.

[8]  J. Zamorano,et al.  Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. , 2009, The Journal of allergy and clinical immunology.

[9]  H. Wong,et al.  Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. , 2009, Recent patents on inflammation & allergy drug discovery.

[10]  K. Choo,et al.  IL-1β, IL-6, and RANTES as Biomarkers of Chikungunya Severity , 2009, PloS one.

[11]  R. Medzhitov.  Origin and physiological roles of inflammation , 2008, Nature.

[12]  Cheryl A. Grice,et al.  Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. , 2008, Journal of medicinal chemistry.

[13]  K. Wasan,et al.  Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases , 2008, Pharmaceutical Research.

[14]  J. N. Sharma,et al.  Role of nitric oxide in inflammatory diseases , 2007, Inflammopharmacology.

[15]  Peter A. Ward,et al.  Novel strategies for the treatment of sepsis , 2003, Nature Medicine.

[16]  C. Natanson,et al.  Anti-inflammatory therapies in sepsis and septic shock , 2000, Expert opinion on investigational drugs.

[17]  Annotated Patent Selections. , 2011, Expert opinion on therapeutic patents.

[18]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[19]  P. Puccetti,et al.  Immune regulation and tolerance to fungi in the lungs and skin. , 2008, Chemical immunology and allergy.

[20]  C. Peifer,et al.  New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. , 2006, Current topics in medicinal chemistry.